Yifan Pharmaceutical Co Ltd - Strategy, SWOT and Corporate Finance Report
SummaryYifan Pharmaceutical Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company.
Key Highlights
Yifan Pharmaceutical Co Ltd (Yifan) develops, manufactures, markets active pharmaceutical ingredients, medical products and polymer materials. The company's products include Chinese traditional medicines, women's health medicines, hematologic maliganancies, inflammatory, endocrinology/metabolic, dermatological, gynecologic and pediatric diseases and among others. The company develops products based on its proprietary DiKine dimeric cytokine platform and iTab immune therapy antibody platform. Its pipeline products are targeted for the treatment of neutropenia, alcoholic hepatitis, acute pancreatitis, solid tumors, B-cell leukaemia, and others. Yifan is headquartered in Hangzhou, Zhejiang, China.
Scope
- Detailed information on Yifan Pharmaceutical Co Ltd required for business and competitor intelligence needs
- A study of the major internal and external factors affecting Yifan Pharmaceutical Co Ltd in the form of a SWOT analysis
- An in-depth view of the business model of Yifan Pharmaceutical Co Ltd including a breakdown and examination of key business segments
- Intelligence on Yifan Pharmaceutical Co Ltd's mergers and acquisitions (MandA), strategic partnerships and alliances, capital raising, private equity transactions, and financial and legal advisors
- News about Yifan Pharmaceutical Co Ltd, such as business expansion, restructuring, and contract wins
- Large number of easy-to-grasp charts and graphs that present important data and key trends
Reasons To Buy
- Gain understanding of Yifan Pharmaceutical Co Ltd and the factors that influence its strategies.
- Track strategic initiatives of the company and latest corporate news and actions.
- Assess Yifan Pharmaceutical Co Ltd as a prospective partner, vendor or supplier.
- Support sales activities by understanding your customers' businesses better.
- Stay up to date on Yifan Pharmaceutical Co Ltd's business structure, strategy and prospects.
Archer Daniels Midland is a human and animal nutrition and an agricultural origination and processing company. The company has three segments: Ag Services and Oilseeds, which includes activities related to the origination, merchandising, transportation, and storage of agricultural raw materials, and the crushing and further processing of oilseeds such as soybeans and soft seeds into vegetable oils and protein meals; Carbohydrate Solutions, which is engaged in corn and wheat wet and dry milling and other activities; and Nutrition, which engages in the manufacturing, sale, and distribution of an array of products including plant-based proteins, natural flavor ingredients, and flavor systems.
MarketLine, a world-leading provider of commercial intelligence, has over 400 experienced analysts, consultants, and researchers with regional and sector expertise in market sizing, competitor tracking, socio and macro economics, and business drivers.
For more than 15 years MarketLine has supported the research needs of investment banks, corporations, professional services firms, and academia with a unique mix of company, industry, country, city and financial data for every major industry and marketplace.
MarketLine’ holistic business intelligence report collection includes:
Industry Intelligence
‒ Industry Profiles
‒ Market Forecasts
‒ Porter’s Five Forces Analysis
Company Intelligence
‒ Company Profiles
‒ SWOT Analysis
‒ Financial Deals
Country and City Intelligence
‒ Country and City Profiles
‒ PEST/PESTLE Analysis
‒ Socio and macro-economic indicators
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.